^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF8 expression

    i
    Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
    Entrez ID:
    943
    Related biomarkers:
    Expression
    Others
    Apply
    Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (A051902) (NCT04803201)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/08/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous
    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery (NCT03007030)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/05/2017
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    TNFRSF8
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (LCCC1637) (NCT03264131)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/11/2018
    Primary completion :
    12/15/2023
    Completion :
    12/15/2028
    TNFRSF8
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
    Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (NCI-2022-03831) (NCT05357794)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/13/2022
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    TNFRSF8 • CD4
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression (SGN35-032) (NCT04569032)
    Phase 2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/12/2020
    Primary completion :
    05/09/2024
    Completion :
    12/31/2025
    TNFRSF8
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
    Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (E4412) (NCT01896999)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/07/2014
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-1 • CD4 • LGALS1 • ICOS
    |
    TNFRSF8 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) (NCT01352520)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/01/2011
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    TNFRSF8
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (NCT04234048)
    Phase 1
    SciTech Development, LLC
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/18/2023
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    TNFRSF8
    |
    TNFRSF8 expression
    |
    fenretinide nanoparticle (ST-001 nanoFenretinide)
    A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) (SGN35-015) (NCT01716806)
    Phase 2
    Seagen Inc.
    Completed
    Last update posted :
    06/11/2024
    Initiation :
    10/31/2012
    Primary completion :
    04/07/2023
    Completion :
    09/12/2023
    TNFRSF8
    |
    TNFRSF8 expression
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine
    A Safety Study of SGN-35T in Adults With Advanced Cancers (NCT06120504)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    05/28/2024
    Initiation :
    02/29/2024
    Primary completion :
    06/30/2027
    Completion :
    04/30/2030
    ALK • TNFRSF8
    |
    TNFRSF8 expression
    To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) (NCT06072131)
    Phase 3
    Acrotech Biopharma Inc.
    Recruiting
    Last update posted :
    05/27/2024
    Initiation :
    10/04/2023
    Primary completion :
    07/01/2030
    Completion :
    11/01/2030
    ALK • TNFRSF8 • UGT1A1
    |
    TNFRSF8 expression • UGT1A1*1*1
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)
    Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma (NCT05949944)
    Phase 1/2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    08/15/2023
    Primary completion :
    08/01/2026
    Completion :
    12/01/2026
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 expression • ALK negative
    |
    Itari (linperlisib)